Mobile

International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung c...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004557-10

International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To compare overall survival (OS) in patients randomized to gemcitabine/cisplatin + PF-3512676 (Investigational Treatment Arm) versus that in patients randomized to gemcitabine/cisplatin alone (Control Treatment Arm)

Critère d'inclusion

  • First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)

Liens